Cargando…
Nanobody-based CAR-T cells for cancer immunotherapy
Chimeric antigen receptor T-cell (CAR-T) therapy is the result of combining genetic engineering-based cancer immunotherapy with adoptive cell therapy (ACT). CAR-T therapy has been successful in treating various types of hematological cancers. CARs are receptors made of an extracellular domain, a mem...
Autores principales: | Safarzadeh Kozani, Pouya, Naseri, Abdolhossein, Mirarefin, Seyed Mohamad Javad, Salem, Faeze, Nikbakht, Mojtaba, Evazi Bakhshi, Sahar, Safarzadeh Kozani, Pooria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036779/ https://www.ncbi.nlm.nih.gov/pubmed/35468841 http://dx.doi.org/10.1186/s40364-022-00371-7 |
Ejemplares similares
-
CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil
por: Nasiri, Fatemeh, et al.
Publicado: (2022) -
Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?
por: Safarzadeh Kozani, Pouya, et al.
Publicado: (2022) -
Novel antigens of CAR T cell therapy: New roads; old destination
por: Safarzadeh Kozani, Pooria, et al.
Publicado: (2021) -
Humanized Chimeric Antigen Receptor (CAR) T cells
por: Kozani, Pouya Safarzadeh, et al.
Publicado: (2021) -
CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit?
por: Safarzadeh Kozani, Pouya, et al.
Publicado: (2021)